The effect of allopurinol on cardiovascular outcomes in patients with type 2 diabetes: a systematic review.

Hormones (Athens, Greece) Pub Date : 2022-12-01 Epub Date: 2022-10-05 DOI:10.1007/s42000-022-00403-9

Evanthia Bletsa, Stavroula A Paschou, Vasiliki Tsigkou, Panagiota K Stampouloglou, Vasiliki Vasileiou, Georgia N Kassi, Evangelos Oikonomou, Gerasimos Siasos

{"title":"The effect of allopurinol on cardiovascular outcomes in patients with type 2 diabetes: a systematic review.","authors":"Evanthia Bletsa, Stavroula A Paschou, Vasiliki Tsigkou, Panagiota K Stampouloglou, Vasiliki Vasileiou, Georgia N Kassi, Evangelos Oikonomou, Gerasimos Siasos","doi":"10.1007/s42000-022-00403-9","DOIUrl":null,"url":null,"abstract":"Background: Cardiovascular disease (CVD) remains the main cause of death in patients with type 2 diabetes (T2D). Although hyperuricemia has been associated with multiple CV complications, it is not officially recognized as a target parameter for CVD risk reduction.Aim: To systematically review the literature in order to determine whether treating hyperuricemia with allopurinol in patients with T2D reduces CVD risk.Methods: A thorough literature search in the PubMed, CENTRAL, and EMBASE databases from inception to August 2022 was performed. After application of selection criteria, 6 appropriate studies were identified.Results: Detailed analysis of the data derived indicated that there is an association between allopurinol treatment and CV benefits, resulting in a reduced risk of CVD events and mortality rates. This association can be attributed mainly to the reduction of inflammation and oxidative burden, as well as to the improvement of glycemic and lipid profiles.Conclusions: This systematic review provides evidence that allopurinol may reduce CVD risk in patients with T2D. Randomized, placebo-controlled trials should be performed in order to confirm these findings and identify specific subgroups of patients who will benefit most.","PeriodicalId":520640,"journal":{"name":"Hormones (Athens, Greece)","volume":" ","pages":"599-610"},"PeriodicalIF":0.0000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hormones (Athens, Greece)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s42000-022-00403-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/10/5 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Cardiovascular disease (CVD) remains the main cause of death in patients with type 2 diabetes (T2D). Although hyperuricemia has been associated with multiple CV complications, it is not officially recognized as a target parameter for CVD risk reduction.

Aim: To systematically review the literature in order to determine whether treating hyperuricemia with allopurinol in patients with T2D reduces CVD risk.

Methods: A thorough literature search in the PubMed, CENTRAL, and EMBASE databases from inception to August 2022 was performed. After application of selection criteria, 6 appropriate studies were identified.

Results: Detailed analysis of the data derived indicated that there is an association between allopurinol treatment and CV benefits, resulting in a reduced risk of CVD events and mortality rates. This association can be attributed mainly to the reduction of inflammation and oxidative burden, as well as to the improvement of glycemic and lipid profiles.

Conclusions: This systematic review provides evidence that allopurinol may reduce CVD risk in patients with T2D. Randomized, placebo-controlled trials should be performed in order to confirm these findings and identify specific subgroups of patients who will benefit most.

查看原文本刊更多论文

别嘌呤醇对2型糖尿病患者心血管预后的影响：一项系统综述

背景：心血管疾病（CVD）仍然是2型糖尿病（T2D）患者死亡的主要原因。尽管高尿酸血症与多种心血管并发症有关，但它并未被正式认定为降低心血管疾病风险的目标参数。目的：系统地回顾文献，以确定用别嘌呤醇治疗T2D患者的高尿酸血症是否能降低CVD的风险。方法：全面检索PubMed、CENTRAL和EMBASE数据库自成立至2022年8月的文献。应用选择标准后，确定了6项合适的研究。结果：对所得数据的详细分析表明，别嘌呤醇治疗与心血管获益之间存在关联，导致心血管事件风险降低和死亡率降低。这种关联主要归因于炎症和氧化负担的减少，以及血糖和脂质谱的改善。结论：本系统综述提供了别嘌呤醇可降低T2D患者心血管疾病风险的证据。应该进行随机、安慰剂对照试验，以证实这些发现，并确定最受益的特定亚组患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hormones (Athens, Greece)

自引率

0.00%

发文量